Form 4: Edwards Lifesciences Director Paul A. Laviolette Reports Stock Grant

Director Paul A. Laviolette reports the acquisition of 3,055 shares of Edwards Lifesciences Corp. common stock through a restricted stock unit grant.

Summary

• Paul A. Laviolette, a director of Edwards Lifesciences Corp., filed a Form 4 on May 9, 2024, reporting a change in beneficial ownership.
• On May 8, 2024, Laviolette acquired 3,055 shares of common stock through a grant of restricted stock units.
• These restricted stock units were granted under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program.
• The restricted stock units are scheduled to vest 100% after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
• Following the transaction, Laviolette beneficially owns 10,773 shares of Edwards Lifesciences Corp. common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices and aligns director interests with shareholders.

Positives

• The grant of restricted stock units aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The restricted stock units will vest after one year or at the next annual meeting.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns director interests with shareholder value.
• Employees: The grant is part of the overall compensation structure.

Key Dates